ClinicalTrials.gg
CompletedNCT02814643ALIZEUpdated Oct 24, 2018Results posted

Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma

A Phase 3 interventional study of Benralizumab and Benralizumab Placebo in Asthma, sponsored by AstraZeneca. Completed at 24 sites in United States. Open to participants aged 12 Years to 21 Years. Per ClinicalTrials.gov, last updated 2018-10-24.

Sponsored by AstraZeneca · Phase 3, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
103
Allocation
Randomized
Ages
12 Years to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.

Enrollment
25th of 39
103 · median 128
Started
2016
with 4 others
Phase 3
20 of 39
1 open now
Registered
15th of 39
by date
Lead sponsor
24 of 39
AstraZeneca

Among the 39 studies testing benralizumab in Asthma, this one is the 25th largest by enrollment, is one of 5 that started in 2016, is one of 20 in phase 3, and was the 15th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About benralizumab

benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing benralizumab in Asthma, or all of them as a file.
02

Study summary

This is a randomized, double-blind, parallel group, placebo-controlled study designed to investigate the potential effect of a fixed dose of benralizumab administered subcutaneously (SC) on antibody responses following seasonal influenza virus vaccination

Read the detailed description

This study is designed to investigate the potential effect of benralizumab on the antibody response to the seasonal influenza virus vaccine in patients 12-21 years of age with asthma. Benralizumab will be given subcutaneously (SC) at Weeks 0, 4, and 8 weeks, at which time benralizumab levels will reach steady state. Patients will then receive 1 dose of intramuscular (IM) seasonal influenza virus vaccine at Week 8 and samples drawn at Week 8 and Week 12 to measure the antibody response to the influenza virus

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Male and female adolescent patients
  • severe asthma
04

Who can participate

Ages eligible
12 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female and male patients aged 12 to 21 years, inclusive, at the time of Visit 1
  • Weight of ≥40 kg
  • Documented history of current treatment with Inhaled (ICS) and long-acting β2 agonists (LABA)
  • Morning pre-bronchodilator (FEV1) of >50% predicted at Visit 1 or Visit 2.
  • Airway reversibility (FEV1 >12% and 200 ml) demonstrated at Visit 1 or Visit 2 using the Maximum Post-bronchodilator Procedure OR
  • Airway reversibility documented in the previous 12 months prior to Visit 1
  • An exacerbation, 1 or more, that required oral corticosteroids in the previous year OR
  • Any condition assessed by patient recall over the previous 2-4 weeks

Exclusion criteria

Exclusion Criteria:

  • pulmonary disease other than asthma
  • Known history of allergy or reaction to the Product formulation or influenza vaccine
  • Receipt of an influenza vaccine within 90 days prior to randomization
  • Poorly controlled asthma during the screening period that requires treatment with oral or a hospitalization/emergency room visit for the treatment of asthma
  • Acute illness or evidence of significant active infection or known influenza infection during the current flu season
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
103 participants (actual)

Study arms

  • Experimental
    Benralizumab

    1 mL fill volume administered every 4 weeks for 3 doses (Weeks 0, 4, and 8). Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.

    Drug: Benralizumab · Drug: Seasonal influenza virus vaccine

  • Placebo comparator
    Placebo

    1 mL fill volume administered every 4 weeks for 3 doses (Weeks 0, 4, and 8). Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.

    Drug: Benralizumab Placebo · Drug: Seasonal influenza virus vaccine

Interventions

  • Benralizumab SC administered every 4 weeks for 3 doses (Weeks 0, 4, and 8).

  • DrugBenralizumab Placebo

    Placebo administered every 4 weeks for 3 doses (Weeks 0, 4, and 8).

  • DrugSeasonal influenza virus vaccine

    Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.

06

What researchers measure

Primary outcomes

  1. Postdose Strain-specific Hemagglutination-inhibition (HAI) Antibody Geometric Mean Fold Rise From Week 8 to Week 12

    To compare the geometric mean fold rises in influenza strain-specific hemagglutination-inhibition responses from Week 8 to Week 12 between patients receiving benralizumab 30mg and patients receiving placebo. Geometric mean fold rise was defined as antilog(z) (mean \[log(z) x\]), where "x" is the postdose HAI antibody titer fold rise from Week 8 and "z" is the natural logarithm.

    Time frame: 4 weeks

  2. Postdose Strain-specific Hemagglutination-inhibition Antibody Geometric Mean Titers Obtained at Week 12

    To compare the geometric mean titers of hemagglutination-inhibition antibody as a measure of influenza strain-specific response at Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.

    Time frame: 12 weeks

  3. Proportion of Patients Who Experienced a Strain-specific Postdose Antibody Response at Week 12 With Antibody Response Defined as a ≥4-fold Rise in Hemagglutination-inhibition Antibody Titer From Week 8 to Week 12

    To compare the proportions of patients experiencing influenza strain-specific responses as measured by ≥4-fold rises in hemagglutination-inhibition antibody titer from Week 8 to Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.

    Time frame: 4 weeks

  4. Proportion of Patients Who Achieved a Strain-specific Postdose Hemagglutination-inhibition Antibody Titer ≥40 at Week 12

    To compare the proportions of patients experiencing influenza strain-specific responses as measured by ≥40-fold rises in hemagglutination-inhibition antibody titer at Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.

    Time frame: 12 weeks

Secondary outcomes

  1. Proportion of Patients Who Achieved a Strain-specific Postdose Hemagglutination Inhibition Antibody Titre ≥320 at Week 12

    To compare the proportions of patients experiencing influenza strain-specific responses as measured by ≥320-fold rises in hemagglutination-inhibition antibody titer at Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.

    Time frame: 12 weeks

  2. Postdose Strain-specific Microneutralization Antibody Geometric Mean Fold Rise From Week 8 to Week 12

    To compare the geometric mean fold rises in influenza strain-specific microneutralization antibody responses from Week 8 to Week 12 between patients receiving benralizumab 30mg and patients receiving placebo. Geometric mean fold rise was defined as antilog(z) (mean \[log(z) x\]), where "x" is the postdose microneutralization antibody titer fold rise from Week 8 and "z" is the natural logarithm.

    Time frame: 4 weeks

  3. Postdose Strain-specific Serum Microneutralization Antibody Geometric Mean Titers Obtained at Week 12

    To compare the geometric mean titers of microneutralization antibody as a measure of influenza strain-specific response at Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.

    Time frame: 12 weeks

  4. Proportion of Patients Who Experience a Strain-specific Postdose Antibody Response at Week 12 With Antibody Response Defined as a ≥4-fold Rise in Microneutralization Antibody Titer From Week 8 to Week 12

    To compare the proportions of patients experiencing influenza strain-specific responses as measured by ≥4-fold rises in microneutralization antibody titer from Week 8 to Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.

    Time frame: 4 weeks

  5. Change From Baseline in Mean Asthma Control Questionnaire 6 (ACQ-6) Score at Week 12

    To compare the change from baseline at Week 12 in mean ACQ-6 score between patients receiving benralizumab 30mg and patients receiving placebo. The ACQ-6 assesses asthma symptoms (nighttime waking, symptoms on waking, activity limitation, shortness of breath, wheezing, and short-acting β2 agonist use). Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The mean ACQ-6 score is the mean of the responses to each question. Mean scores of ≤0.75 indicate well-controlled asthma, scores between 0.75 and ≤1.5 indicate partly controlled asthma, and a score \>1.5 indicates not well controlled asthma

    Time frame: 12 weeks

07

Results

Posted Mar 1, 2018

Participant flow

This study was conducted at 30 study centers in the United States between 01 July 2016 and 24 January 2017

Participant flow — Overall Study
MilestoneBenralizumab 30mgPlacebo
Started5152
Completed5049
Not completed13
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject12

Outcome measures

PrimaryPostdose Strain-specific Hemagglutination-inhibition (HAI) Antibody Geometric Mean Fold Rise From Week 8 to Week 12

To compare the geometric mean fold rises in influenza strain-specific hemagglutination-inhibition responses from Week 8 to Week 12 between patients receiving benralizumab 30mg and patients receiving placebo. Geometric mean fold rise was defined as antilog(z) (mean \[log(z) x\]), where "x" is the postdose HAI antibody titer fold rise from Week 8 and "z" is the natural logarithm.

Time frame:
4 weeks
Reported as:
Geometric least squares mean · Fold change
Postdose Strain-specific Hemagglutination-inhibition (HAI) Antibody Geometric Mean Fold Rise From Week 8 to Week 12
Fold changeBenralizumab 30mgPlacebo
Influenza A H1N13.60 ± 1.223.13 ± 1.22
Influenza A H3N23.25 ± 1.183.85 ± 1.18
Influenza B Yamagata lineage3.42 ± 1.163.17 ± 1.16
Influenza B Victoria lineage4.08 ± 1.193.27 ± 1.19
Statistical analysis
  • Benralizumab 30mg vs Placebo · ANCOVA · Geometric least-square mean ratio: 0.87 · 90% CI 0.56 to 1.35The linear model effects are treatment group as a fixed effect and age group (adolescents and young adults) as fixed categorical covariate.
  • Benralizumab 30mg vs Placebo · ANCOVA · Geometric least-square mean ratio: 1.19 · 90% CI 0.82 to 1.71The linear model effects are treatment group as a fixed effect and age group (adolescents and young adults) as fixed categorical covariate.
  • Benralizumab 30mg vs Placebo · ANCOVA · Geometric least-square mean ratio: 0.93 · 90% CI 0.67 to 1.29The linear model effects are treatment group as a fixed effect and age group (adolescents and young adults) as fixed categorical covariate.
  • Benralizumab 30mg vs Placebo · ANCOVA · Geometric least-square mean ratio: 0.80 · 90% CI 0.54 to 1.19The linear model effects are treatment group as a fixed effect and age group (adolescents and young adults) as fixed categorical covariate.
PrimaryPostdose Strain-specific Hemagglutination-inhibition Antibody Geometric Mean Titers Obtained at Week 12

To compare the geometric mean titers of hemagglutination-inhibition antibody as a measure of influenza strain-specific response at Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.

Time frame:
12 weeks
Reported as:
Geometric least squares mean · Antibody titer
Postdose Strain-specific Hemagglutination-inhibition Antibody Geometric Mean Titers Obtained at Week 12
Antibody titerBenralizumab 30mgPlacebo
Influenza A H1N1521.06 ± 1.13518.60 ± 1.13
Influenza A H3N2170.73 ± 1.15219.35 ± 1.15
Influenza B Yamagata lineage61.47 ± 1.1363.15 ± 1.13
Influenza B Victoria lineage53.10 ± 1.1466.85 ± 1.14
Statistical analysis
  • Benralizumab 30mg vs Placebo · ANCOVA · Geometric least-square mean ratio: 1.00 · 90% CI 0.76 to 1.31The linear model effects are treatment group as a fixed effect and age group (adolescents and young adults) as fixed categorical covariate.
  • Benralizumab 30mg vs Placebo · ANCOVA · Geometric least-square mean ratio: 1.28 · 90% CI 0.93 to 1.77The linear model effects are treatment group as a fixed effect and age group (adolescents and young adults) as fixed categorical covariate.
  • Benralizumab 30mg vs Placebo · ANCOVA · Geometric least-square mean ratio: 1.03 · 90% CI 0.79 to 1.34The linear model effects are treatment group as a fixed effect and age group (adolescents and young adults) as fixed categorical covariate.
  • Benralizumab 30mg vs Placebo · ANCOVA · Geometric least-square mean ratio: 1.26 · 90% CI 0.93 to 1.70The linear model effects are treatment group as a fixed effect and age group (adolescents and young adults) as fixed categorical covariate.
PrimaryProportion of Patients Who Experienced a Strain-specific Postdose Antibody Response at Week 12 With Antibody Response Defined as a ≥4-fold Rise in Hemagglutination-inhibition Antibody Titer From Week 8 to Week 12

To compare the proportions of patients experiencing influenza strain-specific responses as measured by ≥4-fold rises in hemagglutination-inhibition antibody titer from Week 8 to Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.

Time frame:
4 weeks
Reported as:
Number · Proportion of Participants
Proportion of Patients Who Experienced a Strain-specific Postdose Antibody Response at Week 12 With Antibody Response Defined as a ≥4-fold Rise in Hemagglutination-inhibition Antibody Titer From Week 8 to Week 12
Proportion of ParticipantsBenralizumab 30mgPlacebo
Influenza A H1N10.440 (0.32 to 0.57)0.306 (0.20 to 0.43)
Influenza A H3N20.500 (0.38 to 0.62)0.490 (0.37 to 0.62)
Influenza B Yamagata lineage0.480 (0.36 to 0.60)0.490 (0.37 to 0.62)
Influenza B Victoria lineage0.560 (0.43 to 0.68)0.408 (0.29 to 0.54)
PrimaryProportion of Patients Who Achieved a Strain-specific Postdose Hemagglutination-inhibition Antibody Titer ≥40 at Week 12

To compare the proportions of patients experiencing influenza strain-specific responses as measured by ≥40-fold rises in hemagglutination-inhibition antibody titer at Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.

Time frame:
12 weeks
Reported as:
Number · Proportion of Participants
Proportion of Patients Who Achieved a Strain-specific Postdose Hemagglutination-inhibition Antibody Titer ≥40 at Week 12
Proportion of ParticipantsBenralizumab 30mgPlacebo
Influenza A H1N11.00 ± 251.91.00 ± 191.3
Influenza A H3N20.980 ± 136.20.980 ± 168.6
Influenza B Yamagata lineage0.860 ± 144.90.796 ± 115.0
Influenza B Victoria lineage0.780 ± 178.70.878 ± 162.2
SecondaryProportion of Patients Who Achieved a Strain-specific Postdose Hemagglutination Inhibition Antibody Titre ≥320 at Week 12

To compare the proportions of patients experiencing influenza strain-specific responses as measured by ≥320-fold rises in hemagglutination-inhibition antibody titer at Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.

Time frame:
12 weeks
Reported as:
Number · Proportion of Participants
Proportion of Patients Who Achieved a Strain-specific Postdose Hemagglutination Inhibition Antibody Titre ≥320 at Week 12
Proportion of ParticipantsBenralizumab 30mgPlacebo
Influenza A H1N10.840 (0.73 to 0.92)0.857 (0.75 to 0.93)
Influenza A H3N20.500 (0.38 to 0.62)0.612 (0.48 to 0.73)
Influenza B Yamagata lineage0.020 (0.00 to 0.09)0.020 (0.00 to 0.09)
Influenza B Victoria lineage0.080 (0.03 to 0.17)0.041 (0.01 to 0.12)
SecondaryPostdose Strain-specific Microneutralization Antibody Geometric Mean Fold Rise From Week 8 to Week 12

To compare the geometric mean fold rises in influenza strain-specific microneutralization antibody responses from Week 8 to Week 12 between patients receiving benralizumab 30mg and patients receiving placebo. Geometric mean fold rise was defined as antilog(z) (mean \[log(z) x\]), where "x" is the postdose microneutralization antibody titer fold rise from Week 8 and "z" is the natural logarithm.

Time frame:
4 weeks
Reported as:
Geometric mean · Fold change
Postdose Strain-specific Microneutralization Antibody Geometric Mean Fold Rise From Week 8 to Week 12
Fold changeBenralizumab 30mgPlacebo
Influenza A H1N15.1 ± 521.44.4 ± 329.4
Influenza A H3N23.2 ± 149.83.6 ± 210.0
Influenza B Yamagata lineage2.8 ± 148.93.2 ± 141.3
Influenza B Victoria lineage3.8 ± 224.13.5 ± 195.3
SecondaryPostdose Strain-specific Serum Microneutralization Antibody Geometric Mean Titers Obtained at Week 12

To compare the geometric mean titers of microneutralization antibody as a measure of influenza strain-specific response at Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.

Time frame:
12 weeks
Reported as:
Geometric mean · Antibody titer
Postdose Strain-specific Serum Microneutralization Antibody Geometric Mean Titers Obtained at Week 12
Antibody titerBenralizumab 30mgPlacebo
Influenza A H1N13774.1 ± 181.73969.1 ± 154.0
Influenza A H3N24307.5 ± 169.04351.3 ± 171.0
Influenza B Yamagata lineage350.2 ± 103.6336.2 ± 114.3
Influenza B Victoria lineage164.5 ± 178.5234.4 ± 135.0
SecondaryProportion of Patients Who Experience a Strain-specific Postdose Antibody Response at Week 12 With Antibody Response Defined as a ≥4-fold Rise in Microneutralization Antibody Titer From Week 8 to Week 12

To compare the proportions of patients experiencing influenza strain-specific responses as measured by ≥4-fold rises in microneutralization antibody titer from Week 8 to Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.

Time frame:
4 weeks
Reported as:
Number · Proportion of Participants
Proportion of Patients Who Experience a Strain-specific Postdose Antibody Response at Week 12 With Antibody Response Defined as a ≥4-fold Rise in Microneutralization Antibody Titer From Week 8 to Week 12
Proportion of ParticipantsBenralizumab 30mgPlacebo
Influenza A H1N10.420 ± 251.90.408 ± 191.3
Influenza A H3N20.440 ± 136.20.429 ± 168.6
Influenza B Yamagata lineage0.280 ± 144.90.388 ± 115.0
Influenza B Victoria lineage0.400 ± 178.70.388 ± 162.2
SecondaryChange From Baseline in Mean Asthma Control Questionnaire 6 (ACQ-6) Score at Week 12

To compare the change from baseline at Week 12 in mean ACQ-6 score between patients receiving benralizumab 30mg and patients receiving placebo. The ACQ-6 assesses asthma symptoms (nighttime waking, symptoms on waking, activity limitation, shortness of breath, wheezing, and short-acting β2 agonist use). Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The mean ACQ-6 score is the mean of the responses to each question. Mean scores of ≤0.75 indicate well-controlled asthma, scores between 0.75 and ≤1.5 indicate partly controlled asthma, and a score \>1.5 indicates not well controlled asthma

Time frame:
12 weeks
Reported as:
Mean · Score on a scale
Change From Baseline in Mean Asthma Control Questionnaire 6 (ACQ-6) Score at Week 12
Score on a scaleBenralizumab 30mgPlacebo
Change From Baseline in Mean Asthma Control Questionnaire 6 (ACQ-6) Score at Week 12-0.50 (-2.8 to 4.3)-0.42 (-2.7 to 1.2)

Adverse events

Collected over All AEs, including SAEs, were collected from the time the patient, parent, or legal guardian signed the informed consent/assent throughout the treatment period and including the follow-up period (through Week 20).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Benralizumab 30mg0/51 (0%)0/51 (0%)28/51 (54.9%)
Placebo0/52 (0%)2/52 (3.8%)23/52 (44.2%)
Most frequent serious events
Most frequent serious events
EventBenralizumab 30mgPlacebo
Suicidal ideationPsychiatric disorders0/511/52
AsthmaRespiratory, thoracic and mediastinal disorders0/511/52
Most frequent other events
Showing 10 of 14
Most frequent other events
EventBenralizumab 30mgPlacebo
NasopharyngitisInfections and infestations2/514/52
HeadacheNervous system disorders2/514/52
Gastroenteritis viralInfections and infestations3/511/52
Upper respiratory tract infectionInfections and infestations3/511/52
AsthmaRespiratory, thoracic and mediastinal disorders3/513/52
Oropharyngeal painRespiratory, thoracic and mediastinal disorders3/512/52
CoughRespiratory, thoracic and mediastinal disorders0/513/52
Abdominal discomfortGastrointestinal disorders2/510/52
SinusitisInfections and infestations2/511/52
Viral upper respiratory tract infectionInfections and infestations2/510/52

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Benralizumab 30mgPlaceboTotal
Mean16.0 ± 2.6515.7 ± 2.9915.9 ± 2.82
Age, Customized
Age, Customized(Participants)Benralizumab 30mgPlaceboTotal
≥12 to ≤17363672
≥18 to ≤21151631
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Benralizumab 30mgPlaceboTotal
Female212142
Male303161
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Benralizumab 30mgPlaceboTotal
American Indian Or Alaska Native011
Black Or African American131326
Other022
White383674
08

Study locations

24 sites
  • Research Site
    Birmingham, Alabama 35209, United States
  • Research Site
    Mesa, Arizona 85206, United States
  • Research Site
    Huntington Beach, California 92647, United States
  • Research Site
    Newport Beach, California 92663, United States
  • Research Site
    Aurora, Colorado 80012-4016, United States
  • Research Site
    Colorado Springs, Colorado 80907, United States
  • Research Site
    Denver, Colorado 80230, United States
  • Research Site
    Aventura, Florida 33180, United States
  • Research Site
    Miami, Florida 33135, United States
  • Research Site
    Miami, Florida 33173, United States
  • Research Site
    Minneapolis, Minnesota 55402, United States
  • Research Site
    Bellevue, Nebraska 68123, United States
  • Research Site
    Northfield, New Jersey 08225, United States
  • Research Site
    Edmond, Oklahoma 73034, United States
  • Research Site
    Oklahoma City, Oklahoma 73103, United States
  • Research Site
    Medford, Oregon 97504, United States
  • Research Site
    North Charleston, South Carolina 29420, United States
  • Research Site
    Arlington, Texas 76018, United States
  • Research Site
    El Paso, Texas 79903, United States
  • Research Site
    New Braunfels, Texas 78130, United States
  • Research Site
    San Antonio, Texas 78221, United States
  • Research Site
    San Antonio, Texas 78251, United States
  • Research Site
    Waco, Texas 76712, United States
  • Research Site
    Clinton, Utah 84015, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2016 to primary completion in Jan 2017, 6 months.

Results were first posted in Mar 2018, 1 year 1 month after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 6 months is below that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2016
First posted
Jun 28, 2016
StartActual
Jul 1, 2016
Primary completionActual
Jan 24, 2017
CompletionActual
Jan 24, 2017
Results first posted
Mar 1, 2018
Last update
Oct 24, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02814643
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 28, 2016
Start date
Jul 1, 2016
Primary completion
Jan 24, 2017
Completion
Jan 24, 2017
Results posted
Mar 1, 2018
Last update
Oct 24, 2018

Study contacts

Pamela L Zeitlin, M.D. Ph.D.
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion